Cancer's Sneaky Comeback: Scientists Reveal How Tumors Outsmart Treatment
Cancer treatment faces a relentless enemy: drug resistance. Despite advances in therapy, tumors often find ways to survive and return, leaving doctors scrambling for more effective strategies. But here's where it gets controversial: scientists have discovered a surprising survival tactic that cancer cells use to bounce back after targeted therapies—one that doesn't rely on genetic mutations. Researchers at the University of California San Diego have uncovered that cancer cells can hijack an enzyme normally involved in cell death to aid their own survival and regrowth.
"This completely changes how we think about cancer cell death," explains Dr. Matthew J. Hangauer, assistant professor of dermatology at UC San Diego School of Medicine and a member of the Moores Cancer Center. "When cancer cells endure the initial drug treatment, they experience sublethal signals meant to trigger death. Instead of dying, these signals actually help the cells regrow. If we can block this death signaling in the surviving cells, we may be able to prevent tumors from relapsing during therapy."
The global cancer burden and the challenge of early resistance
Cancer claims roughly one in six lives worldwide, with many deaths occurring not because treatment fails immediately, but because tumors develop resistance and resurface. Resistance often emerges gradually over months or years through genetic mutations, akin to how bacteria evolve to withstand antibiotics. These mutation-driven changes are notoriously difficult to manage given the limited arsenal of available drug combinations.
What makes this new discovery so intriguing is that the mechanism appears at the very start of resistance, long before genetic mutations take hold. Because it operates independently of DNA changes, it presents a fresh opportunity for intervention.
"Most research has focused heavily on genetic mutations as the main driver of resistance," says Dr. August F. Williams, a postdoctoral fellow in Hangauer's lab and the first author of the study. "Our findings reveal that non-genetic mechanisms can kick in much earlier than previously thought, and these processes may be targetable with new drugs. This could help patients stay in remission longer and significantly reduce the likelihood of cancer coming back."
Persister cells, death enzymes, and how tumors relapse
In their experiments, the team discovered several critical insights:
* In models of melanoma, lung, and breast cancer, a small group of "persister" cells survived treatment by maintaining low-level activity of a protein called DNA fragmentation factor B (DFFB), which normally helps break down DNA during cell death.
* The activation of DFFB was too weak to kill the cells but strong enough to interfere with the usual growth-suppressing signals, allowing these cells to evade control.
* When researchers removed DFFB, the persister cells remained dormant and did not regrow during drug therapy.
* Interestingly, DFFB is not essential in healthy cells, but it is critical for the regrowth of persister cancer cells. This makes it a compelling target for combination therapies aimed at extending the effectiveness of targeted treatments.
Publication and support for the research
The study was published in Nature Cell Biology and received funding support from the Department of Defense, the National Institutes of Health, and the American Cancer Society. Dr. Hangauer is also a cofounder, consultant, and research funding recipient of Ferro Therapeutics, a subsidiary of BridgeBio.
So here’s the big question for readers: If cancer can exploit a cell death enzyme to survive, how should this change the way we think about treatment strategies? Do we need to shift focus from solely targeting genetic mutations to also disrupting these early, non-genetic survival mechanisms? Share your thoughts and join the debate—this could be the key to redefining how we fight cancer.
